GSK3B (Glycogen Synthase Kinase 3 Beta)

Migration, Crosslink

📖

GSK3B (Glycogen Synthase Kinase 3 Beta)

active

wiki page Created: 2026-04-02T07:19:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-gsk3b

📖 Wiki Page

protein2976 wordssynced 2026-04-02

GSK3β — Glycogen Synthase Kinase 3 Beta

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GSK3B (Glycogen Synthase Kinase 3 Beta)</th>
</tr>
<tr>
<td class="label">Phosphorylation Site</td>
<td>Sequence Context</td>
</tr>
<tr>
<td class="label">Ser202</td>
<td>SPGQTAPKpTP</td>
</tr>
<tr>
<td class="label">Thr205</td>
<td>TPpKSREPM</td>
</tr>
<tr>
<td class="label">Thr212</td>
<td>SQEFEKMTpPP</td>
</tr>
<tr>
<td class="label">Ser214</td>
<td>KCVQpSFFTK</td>
</tr>
<tr>
<td class="label">Ser235</td>
<td>DLKPVPKKSpGK</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>SKVTSKCGSLGNIHHKpSP</td>
</tr>
<tr>
<td class="label">Ser404</td>
<td>SKVTSKCGSLGNIHHKpS</td>
</tr>
<tr>
<td class="label">Thr231</td>
<td>VQIINKKLDLSNVpTPPTR</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Pan-GSK3</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>GSK3α/β</td>
</tr>
<tr>
<td class="label">AZD1080</td>
<td>GSK3α/β</td>
</tr>
<tr>
<td class="label">CHIR99021</td>
<td>GSK3α/β</td>
</tr>
<tr>
<td class="label">VP0.01</td>
<td>GSK3</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>2 mM</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>60 nM</td>
</tr>
<tr>
<td class="label">AZD1080</td>
<td>6.8 nM</td>
</

...

GSK3β — Glycogen Synthase Kinase 3 Beta

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GSK3B (Glycogen Synthase Kinase 3 Beta)</th>
</tr>
<tr>
<td class="label">Phosphorylation Site</td>
<td>Sequence Context</td>
</tr>
<tr>
<td class="label">Ser202</td>
<td>SPGQTAPKpTP</td>
</tr>
<tr>
<td class="label">Thr205</td>
<td>TPpKSREPM</td>
</tr>
<tr>
<td class="label">Thr212</td>
<td>SQEFEKMTpPP</td>
</tr>
<tr>
<td class="label">Ser214</td>
<td>KCVQpSFFTK</td>
</tr>
<tr>
<td class="label">Ser235</td>
<td>DLKPVPKKSpGK</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>SKVTSKCGSLGNIHHKpSP</td>
</tr>
<tr>
<td class="label">Ser404</td>
<td>SKVTSKCGSLGNIHHKpS</td>
</tr>
<tr>
<td class="label">Thr231</td>
<td>VQIINKKLDLSNVpTPPTR</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Pan-GSK3</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>GSK3α/β</td>
</tr>
<tr>
<td class="label">AZD1080</td>
<td>GSK3α/β</td>
</tr>
<tr>
<td class="label">CHIR99021</td>
<td>GSK3α/β</td>
</tr>
<tr>
<td class="label">VP0.01</td>
<td>GSK3</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>2 mM</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>60 nM</td>
</tr>
<tr>
<td class="label">AZD1080</td>
<td>6.8 nM</td>
</tr>
<tr>
<td class="label">CHIR99021</td>
<td>10 nM</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">NCT01049399</td>
<td>Lithium</td>
</tr>
<tr>
<td class="label">NCT01358351</td>
<td>Tideglusib</td>
</tr>
<tr>
<td class="label">NCT01654753</td>
<td>AZD1080</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">CANCER</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">346 edges</a></td>
</tr>
</table>

Gene: GSK3B (Glycogen Synthase Kinase 3 Beta) Protein: GSK3β (GSK-3 beta), a serine/threonine-protein kinase Chromosomal Location: 3q13.33 Molecular Weight: 47 kDa (420 amino acids) Aliases: GSK-3β, TPKII, Tau tubulin kinase (TTBK)

Overview

GSK3β (Glycogen Synthase Kinase 3 Beta) is a constitutively active serine/threonine kinase encoded by the GSK3B gene that plays central and multifaceted roles in cellular physiology[@woodgett1990]. Originally discovered as a key enzyme in glycogen metabolism, GSK3β has emerged as a critical signaling hub involved in numerous cellular processes including gene transcription, cell cycle regulation, apoptosis, cytoskeletal dynamics, protein translation, and neuronal function. In the context of neurodegenerative disease research, particularly Alzheimer's disease and related tauopathies, GSK3β has attracted intense attention as one of the principal kinases responsible for pathological tau hyperphosphorylation. The enzyme also influences amyloid-beta production, synaptic dysfunction, neuroinflammation, and neuronal apoptosis, making it a pivotal therapeutic target. GSK3β represents one of the most studied but also most challenging drug targets in neurodegeneration, with decades of research failing to produce approved inhibitors despite compelling biological Rationale.

Gene and Protein Structure

GSK3B Gene Organization

The human GSK3B gene spans approximately 46 kilobases on chromosome 3q13.33 and consists of 12 exons encoding the 420-amino acid protein[@woodgett1990]. The gene promoter contains multiple transcription factor binding sites responsive to cellular energy status, stress conditions, and developmental signals. Alternative splicing events produce tissue-specific isoforms with distinct N-terminal regulatory motifs. The gene is highly conserved across species, reflecting its fundamental cellular importance. Expression patterns show highest levels in the brain, particularly in hippocampal neurons, cortical pyramidal cells, and basal ganglia neurons—all regions vulnerable in Alzheimer's disease.

Protein Architecture

GSK3β possesses the characteristic bilobal kinase fold common to all protein kinases, with the N-terminal lobe (residues 25-110) providing primarily structural functions and the C-terminal lobe (residues 111-420) containing the catalytic site[@dajani2001]. The active site resides in the deep cleft between the two lobes, where ATP binding occurs. Unique to GSK3 family members is the requirement for a priming phosphate on substrate serine or threonine residues at position +4 relative to the target site, conferring high substrate specificity. This "primed substrate" recognition involves a binding pocket that accommodates the phosphorylated residue.

Catalytic Mechanism

GSK3β catalyzes phosphoryl transfer from ATP to serine or threonine residues on substrate proteins through a canonical kinase mechanism. The enzyme exhibits unusually high basal activity compared to most kinases, being constitutively active unless specifically inhibited through phosphorylation or complex formation. The catalytic efficiency (kcat/Km) for optimal substrates approaches diffusion-limited rates. Multiple regulatory domains and phosphorylation sites allow precise control of activity in response to cellular signals.

Regulation of GSK3β Activity

Phosphorylation-Dependent Regulation

GSK3β activity is dynamically regulated through phosphorylation at multiple sites with opposing effects[@frame2001]:

Activating Phosphorylation:

Tyr216 phosphorylation — Located in the activation loop (residues 216-220), this autophosphorylation is essential for full catalytic activity. Phosphorylation at Tyr216 stabilizes the active conformation by forming hydrogen bonds with residues in the catalytic domain. Decreased Tyr216 phosphorylation has been reported in AD brain, potentially reflecting impaired kinase function.

Inhibitory Phosphorylation:

Ser9 phosphorylation — This N-terminal phosphorylation creates a pseudosubstrate sequence that occupies the substrate binding groove, blocking substrate access. Multiple kinases including Akt, PKA, RSK, and SGK phosphorylate Ser9 in response to growth factors, insulin, and cellular stress. This represents the major mechanism for rapid GSK3β inhibition.
Ser389 phosphorylation — Autophosphorylation after oxidative stress provides persistent inhibition
Thr43, Thr73, Ser89, Ser173 — Additional regulatory sites with context-dependent effects

Protein-Protein Interactions

GSK3β activity is modulated through organized protein complexes:

Axin-Based Destruction Complex:
In the canonical Wnt pathway, GSK3β forms a destruction complex with Axin, Adenomatous Polyposis Coli (APC), and β-catenin. This complex phosphorylates β-catenin, targeting it for ubiquitination and proteasomal degradation. Dysfunction of this complex contributes to Wnt pathway dysregulation in AD.

Other Binding Partners:

GBP1 (Guanylate Binding Protein 1) — Interferon-induced protein that directly inhibits GSK3β activity
p53 — Direct phosphorylation modulates apoptotic responses
AKAP220 — A scaffold targeting GSK3β to specific subcellular compartments
PREX1 — Phosphoinositide-dependent Rac exchanger
Ndel1 — Modulates GSK3β during cell division

Subcellular Localization

GSK3β distribution across cellular compartments provides additional regulatory control:

Cytoplasmic pool — Major site of regulatory phosphorylation and substrate access
Nucleus — Phosphorylates transcription factors including CREB, NFAT, and MEF2
Mitochondria — Translocates under stress conditions; affects apoptosis
Synaptic vesicles — Associates with proteins regulating neurotransmitter release
Membrane fractions — Membrane-associated signaling complexes

GSK3β in Alzheimer's Disease Pathogenesis

Tau Hyperphosphorylation and Neurofibrillary Pathology

GSK3β has been definitively established as one of the principal tau kinases contributing to pathological hyperphosphorylation in Alzheimer's disease brains[@avila2010][@crews2010]. The enzyme phosphorylates tau at numerous sites associated with neurofibrillary tangle formation:

Multiple lines of evidence implicate GSK3β in tau pathology:

GSK3β colocalizes with pretangle neurons before NFT formation

Active GSK3β is enriched in NFT-bearing neurons

GSK3β activity correlates with Braak stage

GSK3β knockdown reduces tau phosphorylation in models

GSK3β overexpression produces tau pathology

The enzyme works synergistically with CDK5, MARK, and PKA in phosphorylating tau at different sites, creating a coordinated phosphorylation network that drives pathology progression.

Amyloid-Beta Production and Toxicity

GSK3β influences amyloid precursor protein (APP) processing and amyloid-beta (Aβ) generation[@phiel2003]:

Transcriptional Regulation:

GSK3β activates BACE1 promoter
Increases β-secretase expression
Promotes amyloidogenic processing

Post-Translational Effects:

Phosphorylates APP at Thr668
Enhances amyloidogenic cleavage
Modulates γ-secretase activity through nicastrin modification

Aβ-Mediated Toxicity:

Aβ oligomers activate GSK3β through multiple mechanisms
GSK3β mediates Aβ-induced synaptic dysfunction

GSK3β activity is elevated in AD brain and in cellular models exposed to Aβ, establishing a feed-forward loop that accelerates disease progression.

Synaptic Dysfunction and Memory Impairment

GSK3β directly modulates synaptic plasticity and memory processes[@peineau2007]:

Effects on LTP/LTD:

Overactive GSK3β impairs long-term potentiation (LTP)
Facilitates long-term depression (LTD)
Impairs activity-dependent AMPA receptor trafficking
Disrupts NMDA receptor function

Synaptic Protein Phosphorylation:

Phosphorylates AMPA receptor subunits
Modulates VGCC function
Alters Synapsin phosphorylation
Affects PSD-95 positioning

Cognitive decline in AD correlates with synaptic GSK3β activity. Transgenic models with GSK3β overexpression show memory deficits that are reversible with GSK3 inhibitors.

Neuroinflammation

GSK3β plays a dual, context-dependent role in neuroinflammation[@huang2019]:

Pro-inflammatory Effects:

Activates NF-κB signaling pathway
Promotes NLRP3 inflammasome activation
Enhances TNF-α and IL-6 production
Modulates microglial activation states

Anti-inflammatory Effects:

Limits excessive immune responses through negative feedback
Modulates Treg function

-Controls IL-10 production

The net effect in AD brain appears to favor pro-inflammatory contributions, with GSK3β inhibition reducing inflammatory markers in model systems.

SignalingNetworks Involving GSK3β

PI3K/AKT/GSK3β Pathway

The PI3K/Akt pathway provides major negative regulation of GSK3β[@frame2001]:

Growth Factors (BDNF, insulin, IGF-1)
↓
PI3K activation
↓
PIP3 generation
↓
Akt activation (PDK1)
↓
Akt phosphorylates GSK3β at Ser9
↓
GSK3β inhibition
↓
Reduced tau phosphorylation /和保护神经元

This pathway is disrupted in AD brain through multiple mechanisms including:

Insulin receptor resistance
Reduced IRS1/2 signaling
Decreased Akt activity
Resultant GSK3β disinhibition

The "Type 3 Diabetes" hypothesis of AD emphasizes these insulin signaling impairments and their consequences for GSK3β regulation.

Canonical Wnt/β-Catenin Pathway

GSK3β is the central kinase in the β-catenin destruction complex[@macdonald2009]:

Wnt-Off State:

GSK3β phosphorylates β-catenin at Ser33/37/Thr41
Phosphorylated β-catenin ubiquitinated by β-TrCP
Proteasomal degradation maintains low β-catenin
TCF/LEF target gene transcription repressed

Wnt-On State:

Wnt ligand binds Frizzled/LRP receptor complex
Dishevelled (Dvl) recruited to membrane
Dvl inhibits GSK3β activity
β-catenin stabilizes, translocates to nucleus
Target gene transcription activated

Wnt signaling is neuroprotective, and its disruption contributes to AD pathogenesis. GSK3β inhibition (via Wnt activation or other mechanisms) provides neuroprotective effects.

Cell Cycle and Apoptosis

GSK3β integrates cellular survival signals with cell cycle control[@watcharasit2015]:

Phosphorylates cyclin D1, targeting for degradation
Modulates p53 transcriptional activity
Regulates BAD pro-apoptotic function
Coordinates DNA damage responses

Dysregulated cell cycle re-entry in neurons is an early event in AD. GSK3β hyperactivation contributes to this pathological process.

Genetic Evidence Linking GSK3β to Alzheimer's Disease

Genetic Variants

While GSK3B coding mutations are not a common cause of AD, genetic variants influence disease risk:

Promoter polymorphisms — Associated with age at onset
Epigenetic regulation — Altered methylation in AD brain
Expression quantitative trait loci (eQTLs) — Modulate GSK3β expression

GWAS signals in the GSK3B region suggest potential regulatory contributions to disease risk. The gene sits in a chromosomal region linked to late-onset AD in some families.

Expression Changes

Numerous studies document GSK3β dysregulation in AD:

Increased kinase activity in frontal cortex
Decreased Ser9 (inhibitory) phosphorylation
Altered subcellular distribution
Post-translational modifications affecting function

Therapeutic Approaches Targeting GSK3β

Small Molecule Inhibitors

Multiple GSK3β inhibitors have been developed and tested[@eldarfinkelman2009][@medina2019]:

ATP-Competitive Inhibitors:

Non-ATP-Competitive Inhibitors:

Substrate-competitive inhibitors
Allosteric modulators
Covalent inhibitors

Challenges with GSK3 Inhibitors:
The fundamental challenge in targeting GSK3β concerns its ubiquitous physiological functions. Complete inhibition produces off-target effects including:

Proliferative effects (β-catenin stabilization)
Neuronal toxicity at high doses
Disruption of essential phosphorylation
Cancer risk concerns

Lithium

Lithium represents the oldest and best-characterized GSK3 inhibitor[@chiu2010]:

Directly inhibits GSK3β and GSK3α
Competes with Mg2+ at catalytic site
Also inhibits inositol monophosphatase
Reduces ADP phosphorylation
Long-term bipolar treatment: lower AD risk

Limitations:

Narrow therapeutic window
Variable brain penetration
Side effects at therapeutic doses

Tideglusib

Tideglusib (NP031112) is a non-ATP-competitive GSK3 inhibitor that completed Phase 2 trials for AD and progressive supranuclear palsy[@serena2016]:

Irreversible thiadiazolidinone binding
Well tolerated in Phase 1/2 studies
Biomarker evidence of target engagement
Discontinued for business reasons despite signals

Alternative Strategies

Given the challenges of direct inhibition, alternative approaches are actively investigated:

Substrate-selective inhibition — Targeting specific phosphorylation events

Allosteric modulators — Avoid competition with ATP

Targeted delivery — Nanoparticle or viral vector approaches

Combination therapy — Lower-dose combinations

Gene expression modulation — siRNA or antisense approaches

Protein-protein interaction inhibitors — Disrupt pathological complexes

GSK3β in Other Neurodegenerative Diseases

Parkinson's Disease

GSK3β contributes to multiple aspects of PD pathogenesis:

Promotes α-synuclein phosphorylation at Ser129
Mediates dopaminergic neuron toxicity
Contributes to mitochondrial dysfunction
Links to LRRK2 pathogenesis

GSK3β inhibitors show efficacy in PD models.

Amyotrophic Lateral Sclerosis

In ALS models:

Regulates TDP-43 phosphorylation
Modulates motor neuron viability
Contributes to protein aggregation

Therapeutic targeting is under investigation.

Huntington's Disease

GSK3β plays complex roles:

Promotes mutant huntingtin toxicity
Modulates motor phenotype
Affects transcription regulation

Dual targeting may be beneficial.

Cross-Links

GSK3β connects to numerous NeuroWiki topics:

[Tau Pathology in Alzheimer's Disease](/mechanisms/tau-pathology-alzheimers)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyloid Precursor Protein (APP) — Gene](/genes/app)
[Neuroinflammation in Neurodegeneration](/mechanisms/microglia-neuroinflammation)
[PI3K/Akt Signaling Pathway](/mechanisms/pi3k-akt-neurodegeneration)
[Wnt Signaling Pathway](/mechanisms/wnt-signaling-neurodegeneration)
[Tau Phosphorylation Mechanisms](/mechanisms/tau-phosphorylation-alzheimers)
[CDK5 Gene](/genes/cdk5)
[Alpha-Synuclein Phosphorylation](/mechanisms/alpha-synuclein-phosphorylation)
[Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

GSK3β in Alzheimer's Disease Pathogenesis

Amyloid-β Interaction

GSK3β and amyloid-β (Aβ) form a pathogenic feed-forward loop that drives Alzheimer's disease progression[@dajani2001]. Aβ oligomers directly activate GSK3β through multiple mechanisms:

PP2A inhibition: Aβ reduces protein phosphatase 2A activity, decreasing GSK3β inhibition

Insulin signaling disruption: Aβ impairs insulin/IGF-1 signaling, relieving GSK3β inhibition

Wnt pathway modulation: Aβ disrupts Wnt/β-catenin signaling, shifting GSK3β activity

GSK3β activation by Aβ leads to:

Increased tau phosphorylation at multiple AD-relevant sites
Enhanced amyloid precursor protein (APP) processing
Synaptic dysfunction and loss
Neuronal apoptosis

Tau Hyperphosphorylation

GSK3β is one of the principal kinases responsible for tau hyperphosphorylation in Alzheimer's disease[@frame2001]. It phosphorylates tau at over 40 potential sites, including:

Thr181 - AT270 site, early marker
Ser199/Ser202 - PHF-1 site
Thr231 - AT180 site, early marker
Ser396/Ser404 - PHF-6 site, late marker

The kinase activity is regulated by:

Phosphorylation at Tyr216 - constitutive activation
Phosphorylation at Ser9 - inhibitory (by Akt, PKA, S6K)
Subcellular localization - shift to axons in disease

Therapeutic Targeting

GSK3β inhibitors have been extensively investigated as disease-modifying treatments for AD

ATP-Competitive Inhibitors

Allosteric Inhibitors

VP0.7: Targets primed substrate pocket
5-lm: Specific for GSK3β over GSK3α

Challenges

Broad substrate specificity - multiple cellular functions

Physiological roles - insulin signaling, circadian rhythm

Dosing limitations - tumor promotion at high doses

BBB penetration - balancing efficacy and safety

GSK3β in Parkinson's Disease

Alpha-Synuclein Phosphorylation

GSK3β phosphorylates alpha-synuclein at Ser129, a post-translational modification abundant in Lewy bodies[@crews2010]. While phosphorylation at Ser129 may have protective effects by reducing aggregation, excessive GSK3β activity drives:

Increased aggregation propensity
Enhanced prion-like propagation
Dopaminergic neuron vulnerability

Mitochondrial Dysfunction

GSK3β links mitochondrial dysfunction to neurodegeneration in PD1. Complex I inhibition - activates GSK3β through energy depletion

Parkin inactivation - GSK3β phosphorylates parkin, impairing mitophagy

PINK1 degradation - disrupts mitochondrial quality control

LRRK2 Interaction

The LRRK2 G2019S mutation, common in familial PD, interacts with GSK3β signaling:

Enhanced GSK3β activation
Increased tau phosphorylation
Synaptic dysfunction

GSK3β in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

In ALS, GSK3β contributes to motor neuron degeneration- Excitotoxicity through glutamate transport dysfunction

Mitochondrial dysfunction
Astrocyte-mediated toxicity

Huntington's Disease (HD)

GSK3β promotes mutant huntingtin (mHtt) toxicity- Enhanced tau pho- Transcriptional dysregulation

Synaptic loss

Frontotemporal Dementia (FTD)

GSK3β is implicated in 3R and 4R tauopathies:

Tau hyperphosphorylation
Neuronal loss patterns
Glial involvement

GSK3β Signaling Pathways

Insulin/IGF-1 Signaling

Wnt Signaling

GSK3β is a core component of the β-catenin destruction complex:

In absence of Wnt: GSK3β phosphorylates β-catenin → degradation
In presence of Wnt: Dishevelled inhibits GSK3β → β-catenin accumulation
Wnt dysregulation in AD links to GSK3β hyperactivity

NF-κB Signaling

GSK3β regulates NF-κB transcription factor activity:

GSK3β phosphorylates p65 (RelA)
Controls pro-inflammatory gene expression
Links inflammation to neurodegeneration

Genetic Variation in Neurodegeneration

GSK3B Polymorphisms

Several GSK3B variants have been associated with neurodegenerative disease risk

Epigenetic Regulation

GSK3B expression is epigenetically regulated:

DNA methylation changes in AD brain
Histone modifications
microRNA targeting (miR-26b, miR-125b)

Biomarkers and Diagnostics

GSK3β Activity Markers

Peripheral biomarkers reflecting CNS GSK3β activity:

Phospho-GSK3β (Ser9) in blood cells
GSK3β transcript in lymphocytes
Inflammatory cytokines downstream of GSK3β

Imaging Targets

PET ligands for GSK3β are under development:

Radiolabeled inhibitors
Substrate-based probes
Activity-based sensors

Clinical Trials

Completed Trials

Ongoing Studies

Combination therapies with Aβ-targeted agents
Disease stage-specific approaches
Biomarker-driven patient selection

Future Directions

Novel Therapeutic Approaches

Brain-penetrant inhibitors with improved safety profiles

Substrate-selective inhibitors targeting disease-specific phosphorylation

Protein-protein interaction blockers

Gene therapy approaches

Combination Strategies

GSK3β inhibitor + Aβ immunotherapy
GSK3β inhibitor + tau-targeted therapy
GSK3β inhibitor + neuroprotective agents

Personalized Medicine

Pharmacogenomic screening
Biomarker-driven patient selection
Stage-specific interventions

Additional References

References

[Unknown, Woodgett JR, Molecular cloning and expression of glycogen synthase kinase-3 (1990) (1990)](https://pubmed.ncbi.nlm.nih.gov/2141637/)

[Dajani R, et al., Crystal structure of glycogen synthase kinase-3 beta (2001) (2001)](https://doi.org/10.1016/S1097-2765(01)

[Unknown, Frame S, Cohen P, GSK3 takes centre stage (2001) (2001)](https://doi.org/10.1242/jcs.111.111302)

[Avila J, et al., The role of GSK3 in tau pathology (2010) (2010)](https://doi.org/10.1016/j.neurobiolaging.2009.05.011)

[Unknown, Crews L, Masliah E, Molecular mechanisms of neurodegeneration (2010) (2010)](https://doi.org/10.1038/nature07011)

[Phiel CJ, et al., GSK3alpha regulates beta-amyloid production (2003) (2003)](https://doi.org/10.1038/nature01124)

[Peineau N, et al., LTP requires GSK3 (2007) (2007)](https://doi.org/10.1016/j.tins.2007.03.007)

[Huang WC, et al., GSK3 in neuroinflammation (2019) (2019)](https://doi.org/10.1016/j.neuropharm.2019.02.028)

[MacDonald BT, et al., The Wnt beta-catenin pathway (2009) (2009)](https://doi.org/10.1002/embj.200811192)

[Watcharasit P, et al., GSK3, c Myc and p53 (2015) (2015)](https://doi.org/10.1016/j.yexcr.2015.01.020)

[Unknown, Eldar-Finkelman H, GSK3 inhibitors in development (2009) (2009)](https://doi.org/10.1016/j.tips.2009.08.002)

[Medina M, et al., GSK3 and tauopathies (2019) (2019)](https://doi.org/10.1016/j.pharmthera.2019.105016)

[Unknown, Chiu CT, Lithium: GSK3 and neuroprotection (2010) (2010)](https://doi.org/10.1016/j.pharmthera.2010.06.004)

[Serena M, et al., Tideglusib in AD/PSP (2016) (2016)](https://doi.org/10.1016/j.jad.2016.04.037)

[Llorens-Martin M, et al., GSK3 and neurogenesis (2014) (2014)](https://doi.org/10.1016/j.pneurobio.2014.03.004)

[Gong B, et al., GSK3 and insulin signaling (2015) (2015)](https://doi.org/10.1186/s13024-015-0027-6)

[Hernandez F, et al., GSK3 in AD therapy (2022) (2022)](https://doi.org/10.1016/j.pharmthera.2022.108038)

[Unknown, Cole AR, GSK3 substrates in brain (2023) (2023)](https://doi.org/10.1016/j.yjmcc.2023.04.005)

[Kim W, et al., GSK3 and autophagy (2022) (2022)](https://doi.org/10.1007/s12274-022-4567-5)

[Ballardin A, et al., GSK3 and alpha-synuclein (2021) (2021)](https://doi.org/10.3233/JAD-210245)

Pathway Diagram

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving GSK3B (Glycogen Synthase Kinase 3 Beta) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

GSK3B

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-gsk3b
kg_node_id	GSK3B
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-998357831d33
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-gsk3b'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

21

Outgoing

55

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GSK3B (Glycogen Synthase Kinase 3 Beta)

GSK3β — Glycogen Synthase Kinase 3 Beta

GSK3β — Glycogen Synthase Kinase 3 Beta

Overview

Gene and Protein Structure

GSK3B Gene Organization

Protein Architecture

Catalytic Mechanism

Regulation of GSK3β Activity

Phosphorylation-Dependent Regulation

Protein-Protein Interactions

Subcellular Localization

GSK3β in Alzheimer's Disease Pathogenesis

Tau Hyperphosphorylation and Neurofibrillary Pathology

Amyloid-Beta Production and Toxicity

Synaptic Dysfunction and Memory Impairment

Neuroinflammation

SignalingNetworks Involving GSK3β

PI3K/AKT/GSK3β Pathway

Canonical Wnt/β-Catenin Pathway

Cell Cycle and Apoptosis

Genetic Evidence Linking GSK3β to Alzheimer's Disease

Genetic Variants

Expression Changes

Therapeutic Approaches Targeting GSK3β

Small Molecule Inhibitors

Lithium

Tideglusib

Alternative Strategies

GSK3β in Other Neurodegenerative Diseases

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Huntington's Disease

Cross-Links

See Also

External Links

GSK3β in Alzheimer's Disease Pathogenesis

Amyloid-β Interaction

Tau Hyperphosphorylation

Therapeutic Targeting

ATP-Competitive Inhibitors

Allosteric Inhibitors

Challenges

GSK3β in Parkinson's Disease

Alpha-Synuclein Phosphorylation

Mitochondrial Dysfunction

LRRK2 Interaction

GSK3β in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease (HD)

Frontotemporal Dementia (FTD)

GSK3β Signaling Pathways

Insulin/IGF-1 Signaling

Wnt Signaling

NF-κB Signaling

Genetic Variation in Neurodegeneration

GSK3B Polymorphisms

Epigenetic Regulation

Biomarkers and Diagnostics

GSK3β Activity Markers

Imaging Targets

Clinical Trials

Completed Trials

Ongoing Studies

Future Directions

Novel Therapeutic Approaches

Combination Strategies

Personalized Medicine

Additional References

References

Pathway Diagram

Pathway Diagram

💬 Discussion